Value Partners Intelligent Funds - Chinese Mainland Focus Fund (USD) 55.27 -15.18% +3.60% Allianz Oriental Income - Class AT (USD) Acc. 205.54 -11.99% -6.50% Templeton Global Fund (USD)A (Ydis) 26.26 -8.57% -11.04% First Sentier Asian Bridge Fund (USD) 11.57 -6.99% -5.01% BlackRock...
Fresh from the J.P. Morgan Global Healthcare Conference, founder and CEO of VelaVigo, Jing Li, joins guest speaker Leon Tang in the US and Brian Yang in Beijing to discuss trending topics that stood out at the world's largest biotech investment conference, held in San Francisco over 8-12...
JPM与CFO&IR会议: • Cellebrite comments a positive read for Security Software vendors with government exposure. Global government changes (U.S., Canada, Germany, France, etc.) are playing a role in a finite number of deals which management sized at $5mm. Cellebrite has been selected to be...
jpm全球资产配置.pdf,is no breadth to this sell off. The J.P. Morgan View Patience • Asset allocation –– Lack of breadth and no smoking gun l us this is one more correction. We advice patience and stay long risk. • Economics –– Data provide litt
Question: The global focus on obesity, ADCs, and autoimmune diseases is evident. How are these influencing investment trends and cross-border collaborations? David Lau:The landscape is significantly influenced by advancements in treatments, particularly for obesity. GLP-1 drugs, led by Eli Lilly and...
April 10, 2025 · 3 min read · Annalee Armstrong Funding Tempest Scrambles for Ways to Bankroll Late-Stage Liver Cancer Asset April 10, 2025 · 2 min read · Tristan Manalac Neuroscience Annexon Touts ‘Rapid’ and ‘Durable’ Improvements for Targeted Guillain-Barré Therapy ...
so it's premature what I'm about to do. But I just want to say I'd be -- and I'd be remiss not to say that he's a young man who joined the company at 20 years old in Argentina. He ran trading in Argentina, then he ran trading for Latin America, then he ran global emergi...
Global Head of Pharma Partnering Roche Devang Bhuva SVP, Corporate Development Gilead Sciences, Inc. Endpoints News Dealmaking panel Glenn Hunzinger: if you do not have a GLP1 will have a tough time getting a good market price for your company; capital markets are not where they want to be...
View performance data, portfolio details, management information, factsheet, regulatory and other documents
Axioma namedAmaury Daugeas President. Dauge will also continue to serve as Chief Financial Officer, a position he has held since joining Axioma in June 2016. As President, a newly created position, Dauge will focus on enhancing execution and operational management as Axioma’s growth continues ...